
The one diet you won't crash out on: a steady dose of joy
Sheila Das is the writer and host of Flow, a podcast about conversation, and a humanities teacher at Vanier College.
One thing I really like is ice cream. I should introduce myself like that at parties and in job interviews as a crucial fact that every person needs to know about me.
Years ago, when I made my first trip to Italy, my roommate Magali and I would invent reasons to go eat gelato every day. It's my father's birthday! Gelato. It's the patron-saint day of Florence! Gelato. It's Tuesday – and sunny! Gelato. The point is, I ate a lot of gelato, but Italian-style – about 20 millilitres, or six exquisite mini-spoonfuls, each one oozing with such intense flavour that by the last melting mouthful, I was floating.
I lost weight that summer.
Italian serving sizes and real, quality ingredients taught me something. Enjoyment matters. What I think we all can learn from Italians is that enjoyment can be part of a whole diet. 'The Joy Diet,' as I call it, calls for a daily dose of, yes, good food and drink, but also puts people and experiences back on the table. The key idea is to savour. This is not obvious, especially in a North American culture that starts each new year with calls to start a new diet and/or exercise routine right in the middle of winter.
Savouring good food and drink and striving for better health are often placed at opposite ends of a spectrum. But complete abstinence can have its own hazards. Remember last year's guidelines warning against any alcohol consumption? What's missing from the recommendations, for people in Britain at least, is the risk of losing social connection. In The Times of London, Zoe Dare Hall attests that having a local pub 'where you can pop in' is now valued as the key metric for a happy and healthy neighbourhood for Brits. Kim Samuel, author of On Belonging, drives home the point that gathering places, be it pubs, cafés or even gyms, bring us together and help us feel connection.
So savouring is not just about gelato or a pint, but about the other, greater pleasures of company. Whether I knew it at the time or not, the gelato in Italy surely tasted better because I was out with my friend. The origin of the word 'companion,' from the Latin con (with) and pane (bread), holds the magic of this age-old insight: the enjoying of bread, of sustenance, with another person.
Why then do I not savour more regularly? Is it that, just like so many Canadians, I am dealing with professional demands, family health concerns and a social life scattered over mountains and oceans? Or is it something deeper?
After all, the Joy Diet requires but two components: openness to joy, and attention.
As to the first, I'll posit that many of us feel we need to suffer. Why else would fasting as a health technique and elimination diets take off? In the face of constant threats and uncertainty, e.g. economic instability, natural disasters and/or political fears, many of us have taken the route of sacrifice to rebalance our lives by being 'good.' We're yearning for some measure of control, but we're moving in the wrong direction. Blame it, if you wish, on our evolutionary psychology, which primes us to assuage danger before desire.
Are we trying to find a replacement for religious penance, to 'cleanse' ourselves, even while purporting to live in a secular spirit? In this modern vernacular, we have come to equate the trim body with being 'good.' It projects visual evidence of moral qualities like restraint (avoiding temptations), intelligence (I know what to choose), and privilege (hello plastic surgery, costly meds and personal trainers).
It is true that the opposite – a lack of restraint – is also on the rise today. The disinhibition displayed by U.S. President Donald Trump, as noted by columnist Ezra Klein, may suggest a broader cultural embrace of pleasure in these uncertain times. Many of us certainly take great pleasure in mocking those in power these days, perhaps also as a response to a perceived lack of control. But much like eating an entire bag of chips, this only helps us to feel good in the moment, and the flavour quickly dissipates.
The Joy Diet is about rejecting sacrifice and cheap thrills and instead diving into deep contentment that makes us feel fully alive. What does make us truly happy? And how do we get there?
In his 2011 book The Swerve, literary historian Stephen Greenblatt recounts a resurgence in popularity of the Roman philosopher Lucretius during the 1400s. This era, later known as the Renaissance, had a cultural backdrop eerily similar to our own: After centuries of plague and war, people were terrified of the future and bent on sacrificing body and mind, thinking that a certain degree of self-flagellation might earn them mercy from God. A 15th-century humanist and Vatican bureaucrat named Poggio Bracciolini summed up humanity's collective mood at the time as being 'terrified of future catastrophes and thrown into a continuous state of misery and anxiety … always panting for riches and never giving our souls or our bodies a moment's peace.' Sound familiar?
In 1417, it was Bracciolini who rediscovered a dusty manuscript by Lucretius titled On the Nature of Things, in which the author wrote that enjoyment is a natural and logical desire of our human condition. Far from the medieval tendency to place divine purification above all other human needs, Lucretius argued for bringing delight back to the table.
Fast-forward to the present day, as folks try to be virtuous by eliminating sugar, or skipping a happy hour to keep up their workout routine, or even signalling virtue by proclaiming how essentially bad they are in being born 'privileged.' Original (i.e. inherited) sin is alive and well.
Now, while we should give full-throttled support to actions that are geared toward creating a more just society, it is unsurprising that there is pushback against essentialist sin. Most people do not want to live in misery as an inescapable, eternal condition. And rightly not.
As human beings, we are made to seek joy and should allow ourselves to feel it. I propose that we reawaken Lucretius's key insight, and update it for our modern world.
A caveat: Lucretius did remind us that true joy is not just found in sensual pleasure, but in exchange with others. The Joy Diet insists on societal values: making friends, and living justly and magnanimously. Others extend joy to having a dialogue with the past through reading, and by remembering good times.
Where were you the last time you felt deep contentment? Sometimes it is difficult to pin down because we confuse joy with simple pleasures, often purchased and always fleeting. As has been widely noted, pain and (simple) pleasure are opposites, but pain and joy are not. Usually, both occur through dedication to causes outside ourselves, as Desmond Tutu and the Dalai Lama remind us in The Book of Joy. Joy is there to be had in the view from a mountain, or the contemplation of a snowfall seen from your window. We can experience joy by feeling relevant, whether by volunteering on a project in our community, or by nourishing our relationships. Yes, that includes listening to the minutiae of boring stories from your grandmother, or holding the hand of your romantic partner. And by savouring – not quaffing – wine.
Some of you are already feeling guilty reading this. Don't! A friend of mine reminded me that even people in the midst of war, suffering real, debilitating trauma, fall in love. Even people who are ill or dying can cherish laughter. Joy does not minimize the reality of suffering. Neither does it merely provide a temporary reprieve. It is, rather, the pulsating raison d'être of life.
In a recent conversation with activist and author Kazu Haga, we talked about joy from the perspective of long-term civic engagement. Societal transformation, whether in the context of historical events like the abolition of slavery, or contemporary issues of the day like climate action, takes time. And working for it needs endurance. The crash diet of outrage poured into one protest, or a year of them, will not cut it. We need a diet that promotes lifelong habits. Here, Mr. Haga recognizes the need to 'pendulate' between the joy of our everyday life and the efforts of activism to keep us going.
Robert Reich, former secretary of labour for Bill Clinton, wrote the day after the countrywide protests against Donald Trump in April that we must be careful not to burn out. He urged activists to take 'time out for your loved ones. Time out for play. Time out for joy. Time out to dance or sing. Time out to do absolutely nothing.'
If you are aching for change right now in the state of the world, there is no reason to feel bad about joy. It is a psychic necessity.
But it is not just guilt that is stopping us. It is dopamine.
In September, New York Times columnist David Brooks lamented that we are unhappy and lonely because we are easily distracted. We eschew art and even entertainment because they are too demanding. The convenience of our phones devours all our attention, creating a dopamine dependency that hooks us into further scrolling. Yet, while these dopamine hits are easy to come by, they actually end up leading us away from enjoyment.
Reclaiming joy requires us to reclaim our attention. In Stolen Focus, journalist Johann Hari emphasizes that attention is not a personal failing but a structural problem of our modern lives, wherein our devices, our work-creep workdays, and fast-food options, are designed to blur our choices.
The Joy Diet is a conscious effort – not to browbeat ourselves for our existence or our addictions (that's just more guilt), but to open our palates to what is truly delicious.
We need to put the phone away and focus on replacing it with something else. Just as Indiana Jones replaced that golden idol statue with a bag of sand in Raiders of the Lost Ark, our system needs to feel full. Finding something sumptuous – a spoonful of gelato, a leisurely chat, or a book to get lost in – is not a bad place to start to reset our happiness and our health.
In turn, that fulfilment may lead us to resilience in an uncertain world.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBC
12 hours ago
- CBC
Why #SkinnyTok videos are being blocked on TikTok
TikTok has blocked the hashtag #SkinnyTok, following pressure from European officials. According to critics, videos under the hashtag promote disordered eating behaviours disguised as health advice.


National Post
a day ago
- National Post
What eating foods like dark chocolate and berries did to a study group of more than 120,000 people
A new study reveals what drinking tea and eating dark chocolate and berries did for a group of more than 120,000 people. Article content Those foods, as well as fruits like grapes, apples, oranges, and beverages like red wine, all contain flavonoids, which are compounds found in many plant products. Flavonoids can 'help your body function more efficiently while protecting it against everyday toxins and stressors,' per Healthline. The study's authors said those who consumed a diverse range of foods containing flavonoids (such as berries, grapes and dark chocolate) 'could lower their risk of developing serious health conditions and have the potential to live longer,' in a news release. The study has been peer-reviewed. Article content Article content Article content In the study, which was recently published in the journal Nature Food, researchers observed 124,805 participants between the ages of 40 and 70 from the UK Biobank, a large-scale database with biomedical information. The participants were tracked for roughly 10 years and their dietary information was collected using a questionnaire asking them about the frequency in which they ate approximately 200 types of food and 30 beverages. Article content Article content Dr. Benjamin Parmenter, a research fellow at Edith Cowan University in Australia, was the study's first author and co-lead. He said consuming roughly 500 mg of flavonoids a day or more was linked to a 16 per cent lower risk of 'all-cause mortality' (meaning death from any cause). Article content It was also linked to a roughly 10 per cent lower risk of cardiovascular disease, type 2 diabetes, and respiratory disease. Article content A study published in 2025 in peer-reviewed food science journal Foods said, as it pertains to human health, 'flavonoids are recognized for their ability to combat aging, mitigate inflammation, safeguard the nervous system, and promote overall well-being.' However, in another study published in 2022 in the Nutrition Journal, researchers 'observed an increased risk of prostate cancer by higher intake of total flavonoids.' In a study published in 2016 in the Journal of Nutritional Science, researchers called for further studies on flavonoids so their usefulness 'in the diet could be improved for better human health.' Article content Article content 'Over 30 different types of flavonoids are regularly consumed in the human diet. These are found in different types of everyday foods,' Parmenter told National Post over email. Article content Article content A few squares of dark chocolate could be roughly 25 mg of flavonoids. One apple is equal to roughly 100 mg of flavonoids, while one orange is roughly 60 mg. For tea drinkers, one cup of black tea is roughly 300 mg of flavonoids, while the same amount of green tea is roughly 150 mg. Article content 'We observed that consuming a higher quantity and wider diversity of dietary flavonoids, when consumed together, may represent the optimal approach for improving long-term health, compared with increasing either flavonoid quantity or diversity alone,' Parmenter said. Article content Those with the highest flavonoid diversity were more likely to be female, older, have a lower body mass index (BMI), be more physically active and have a higher education and were less likely to be current smokers, according to the study.


Globe and Mail
a day ago
- Globe and Mail
Novo Nordisk Stock: Is It Still a Smart Buy?
Much like the long-term users of its most popular product, Novo Nordisk 's (NYSE: NVO) stock has slimmed down considerably of late. Share prices of the company, which developed and sells weight loss drug Wegovy, have fallen nearly 18% in price since the start of this year. Popularity attracts competition, and investors are growing concerned that the Danish pharmaceutical giant won't be able to compete. I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. An increasingly crowded field Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, when Wegovy became the first GLP-1 drug specifically approved by the Food and Drug Administration (FDA) for that indication in mid-2021. Novo Nordisk's Ozempic was first, but it was used off-label as a weight-loss drug, and had only initially been approved as a diabetes treatment and kidney disease treatment. It's easy to believe in a company when it's riding high and unopposed. But late in 2023, a new entrant was approved -- mighty American pharmaceutical company Eli Lilly (NYSE: LLY) with its own GLP-1 treatment, Zepbound -- giving Novo Nordisk one of the strongest competitors imaginable. Almost certainly, this won't continue to be a two-car race for long. Other companies, both large and small, in the healthcare field are pushing hard to develop their own obesity drugs, with varying degrees of success. Eli Lilly alone is an intimidating presence. A mainstay on the American pharmaceutical scene, it's grown to a massive size, to the point where it's the most valuable pharmaceutical company in the world by market cap. It can leverage its vast resources to develop and market any kind of medicine it wants, and in the obesity segment, it was already nearly there with Zepbound's FDA-approved-for-diabetes sibling drug, Mounjaro. Since then, it seems Zepbound has carved out a significant market share from Wegovy. Precise figures are hard to come by, but according to a Goldman Sachs analysis recently reported by Barron's, Novo Nordisk is clinging to a 51% share of the roughly $28 billion market. Eli Lilly holds the rest. Fragmentation and setbacks Like other pharmaceutical industry pundits, Goldman Sachs is predicting that once other obesity drugs are developed successfully and approved, the market will fragment. That's a wholly believable prediction given the zeal and urgency behind many of those efforts. Meanwhile, Novo Nordisk has taken a series of competitive blows that reduced its lead. A shortage of semaglutide -- the main ingredient of Wegovy -- led the FDA to allow compounding pharmacies to make copies of the molecule, essentially producing new competition. Although the shortage is officially over, it showed that Novo Nordisk would be vulnerable if such a situation reoccurred. Another of the numerous fresh setbacks was a head-to-head clinical trial conducted by Eli Lilly, pitting Zepbound against Wegovy. Last December, the results of the study indicated notably more significant weight loss for participants using Wegovy. One internal development also dented investor sentiment on Novo Nordisk, and that was the company's announcement in mid-May that long-serving CEO Lars Fruergaard Jørgensen was stepping down. When enterprises are humming along pleasantly, they rarely experience a top leader's departure. Fighting back Novo Nordisk isn't just absorbing hurtful blows, though; it's been busy shoring up its defenses. As 2024 came to a close, it scooped up contract drug manufacturer Catalent, bringing Wegovy production more under its direct control. That $16.5 billion deal wasn't cheap by any yardstick, but if the new asset is managed well, it should be more than worth the cost ultimately. Novo Nordisk is also keeping up the pace with its own development activities, attempting to succeed with new medications and/or other indications for Wegovy. Its next-generation obesity treatment CagriSema was essentially a flop. However, the company has already had success winning FDA approval for the versatile Wegovy to treat liver disorder metabolic dysfunction-associated steatohepatitis (MASH), and it's developing the drug for a clutch of other ailments. It also has other medications for different disorders in its pipeline. Meanwhile, a score of researchers modeling the future of the obesity market feel that sales of such drugs will blast through the roof. Projections vary, but a typical one is the latest from Morgan Stanley. In May, the veteran investment bank upped its estimate for the market's peak (predicted to occur in 2035) to $150 billion, well up from its previous assumption of $105 billion. The former number is more than 6 times the $24 billion estimated sales of 2024. The very encouraging news for Novo Nordisk bulls like myself is that even if the market gets highly fragmented with numerous competing products and loses significantly more share -- unlikely, given its first-mover prominence and the strength of the Wegovy brand name -- it'll still be a player in a huge market. Yes, competition can be tough. There are a lot of prizes in this game, and more players are entering it. But I think this original player will manage to hold on and thrive, and I continue to consider Novo Nordisk stock a buy. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor 's total average return is789% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025